Physician profile
Brian M Eklund
NPI 1386635670
$1,028.70
in general payments reported to CMS, 2019-2025
25 companies · $70.19 in 2025
The $70.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.10 · 2020: $11.47 · 2021: $11.08 · 2022: $193 · 2023: $366 · 2024: $352 · 2025: $70.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150.64 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $130.63 | 2023-2024 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $108.78 | 2022-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $108.22 | 2022-2024 | Spravato |
| Abbvie INC. | $70.03 | 2022-2023 | |
| Abbott Laboratories | $45.31 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $41.95 | 2024 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $37.54 | 2024 | Rexulti |
| Averitas Pharma INC. | $34.43 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $32.86 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $30.99 | 2019-2024 | |
| Ultragenyx Pharmaceutical INC. | $26.75 | 2023 | |
| Lilly USA, LLC | $25.33 | 2019-2023 | Trulicity, Mounjaro |
| Ardelyx, INC. | $22.22 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $21.50 | 2025 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $17.58 | 2023 | Aptima |
| Pfizer INC. | $16.68 | 2024 | |
| Medtronic, INC. | $15.89 | 2022 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Almatica Pharma LLC | $14.26 | 2025 | Loreev Xr |
| Lifescan, INC. | $13.51 | 2022 | |
| Exact Sciences Corporation | $13.11 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $12.90 | 2023 | Trintellix |
| Amarin Pharma, INC. | $11.47 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Eklund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.